High Quality Semax/Dihexa/Epitalon/Mots-C/Selank Peptides/ semax 80714-61-0
KOSHER ISO FDA 37 Inquiries
80714-61-0
Pharmaceutical Grade
99%
SHENZHEN
Flying
10g/1kg/ 10kg/ 25kg
2023-09-30
vitamin
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionSEMAX Synthetic is a single, non-glycosylated polypeptide chain containing 7 amino acids, having a molecular mass of 813.92 Dalton and a Molecular formula of C37H51N19O1S.CertificatesBasic Info
-
Product Name:
Semax
Other Name:ACTH (4-7), Pro-Gly-Pro-;ACTH (4-7), Pro-Gly-Pro trifluoroacetate salt;L-Methionyl-L-a-glutamyl-L-histidyl-L-phenylalanyl-L-prolylglycyl-L-proline trifluoroacetate salt;Semax;(PRO8,GLY9,PRO10)ACTH-(4-10);SemaxAcetate;L-METHIONYL-L-Α-GLUTAMYL-L-HISTIDYL-L-PHENYLALANYL-L-PROLYLGLYCYL-L-PROLINE;Peptides Semax
CAS No.:80714-61-0
Molecular Formula:C37H51N9O10S
InChIKeys:AFEHBIGDWIGTEH-YNWVLKOQNA-N
Molecular Weight:813.92
EC Number:253-368-1
Color/Form:white to tan
Categories:
Characteristics-
Density:
1.391±0.06 g/cm3(Predicted)
Boiling Point:1335.2±65.0 °C(Predicted)
Water Solubility:Soluble to 2 mg/ml in water
PKA:3.43±0.20(Predicted)
Critical Temperature & Pressure:-20°C
Research-
Class:
Angiotensin IV-derived oligopeptide / HGF-c-Met potentiator
Status:Research compound — Not FDA approved
Mechanism:A synthetic, orally active, blood-brain-barrier-permeable oligopeptide (Hexanoyl-Tyr-Ile-Ahx-NH₂) derived from angiotensin IV. Dihexa binds hepatocyte growth factor (HGF) with high affinity (Kd = 65 pM) and allosterically potentiates HGF activity at its receptor c-Met, promoting dendritic spinogenesis and synaptogenesis. In preclinical models it was reported to be seven orders of magnitude more potent than BDNF at promoting synapse formation. Note: the foundational 2014 paper (McCoy AT, et al. Neurobiol Learn Mem. 2014) was retracted in 2025.
EC50 (HGF Binding KD):65 pM
Activity note:Dihexa is an HGF potentiator, not a direct receptor agonist. It does not activate c-Met alone but markedly augments HGF-induced c-Met activation at low nanomolar HGF concentrations. Functional synaptogenic activity was reported at 10⁻¹°–10⁻⁻ M (original data now subject to retraction).
Source:Original report: McCoy AT, et al. Neurobiol Learn Mem. 2014;115:112-120 (retracted 2025). Benoist CC, et al. J Pharmacol Exp Ther. 2014;351(3):628-637.
Clinical Development:
References-
PubChem:UNII:Literature:
Benoist CC, et al. J Pharmacol Exp Ther. 2014 — HGF/c-Met mechanism; McCoy AT, et al. Neurobiol Learn Mem. 2014 — Synaptogenesis data (Retracted 2025); Athira Pharma: Fosgonimeton (prodrug) pipeline status
Disclaimer:Dihexa is NOT FDA-approved or EMA-approved as a medicine. It is a research compound only. The foundational 2014 paper describing its synaptogenic potency was retracted in 2025. Its phosphate prodrug fosgonimeton failed a Phase 2/3 Alzheimer’s trial (LIFT-AD, 2024). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
Hazard IdentificationClassification of the substance or mixture
no data available
GHS label elements, including precautionary statements
Pictogram(s) no data available Signal word no data available
Hazard statement(s) no data available
Precautionary statement(s) Prevention no data available
Response no data available
Storage no data available
Disposal no data available
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
vitamin
-
Location:
Room 2-502, Building 6, Luneng Tehran Garden Building, No.8 Changbin Road, Xiuying district, Haikou City, Hainan Province
-
Payment Terms:
TT against copy of documents,TT against B/L draft before shipment
-
Average lead Time:
25
-
Total Annual Revenue:
$2.5 million-$5 million
-
Total Employees:
Less than 5
-
Year of Establishment:
2023
-
-
Inquiry History37 Inquiries
Country Product Purchase Quantity Date Posted
United States
N-Acetyl Semax Amidate N-Acetyl Semax NA-semax 99% powder 80714-61-0
1 G Dec 24, 2024
Poland
Hot Selling N-Acetyl Semax 99% Petide powder NA-semax CAS 80714-61-0 Semax
300 MG Apr 29, 2026
Spain
Semax CAS 80714-61-0
20 PCS May 7, 2026
Mexico
Hot Selling N-Acetyl Semax NA-semax 99% powder 80714-61-0 Semax
300 G Sep 10, 2023
Australia
Semax
10 MG Feb 9, 2026
United States
N-Acetyl Semax Amidate
1 G Aug 8, 2026
United States
Semax
2 G Jun 10, 2026
United States
semax
30 MG Jun 9, 2026
United States
Semax
1 G Apr 10, 2026
Italy
N-Acetyl Semax
120 MG Mar 11, 2026
United States
Semax
10 PCS Aug 19, 2025
Australia
Semax
50 MG Aug 28, 2024
Reunion Island
N-Acetyl Semax
0.1 G Jan 9, 2024
United States
Semax
100 G Sep 7, 2023
South Korea
semax
10 G Jun 16, 2026
United States
Semax
1 G May 31, 2026
United States
semax
10 PCS Apr 28, 2026
United Kingdom
Semax (Met-Glu-His-Phe-Pro-Gly-Pro)
50 MG Apr 16, 2026
Singapore
Semax
20 MG Mar 13, 2026
Brazil
Semax
10 PCS Sep 29, 2025 Post an enquiry for this product